DB
TARA icon

Dmitry Balyasny’s Protara Therapeutics TARA Stock Holding History

Dmitry Balyasny’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.92M Buy
+1,026,691
New +$4.88M ﹤0.01% 1483
2025
Q2 		– Sell
-18,710
Closed -$79.7K – 3333
2025
Q1 		$79.7K Buy
+18,710
New +$83.6K ﹤0.01% 2696

Other funds holding TARA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return

Dmitry Balyasny's TARA Position: Q2 2026 in Review

Dmitry Balyasny opened a new position in Protara Therapeutics (TARA) in Q2 2026: 1,026,691 shares worth $3.92M. The stake represents ﹤0.01% of the portfolio and ranks #1483 among its holdings. This is a return to the name: Dmitry Balyasny previously reported a position in TARA as recently as Q1 2025.

Dmitry Balyasny first reported a position in TARA in Q1 2025 and has held it in 2 quarters since. 118 funds tracked by Wall St. Rank hold TARA as of Q2 2026.

  • Dmitry Balyasny held 1,026,691 shares of Protara Therapeutics worth $3.92M as of Q2 2026.
  • Protara Therapeutics was a new Dmitry Balyasny position in Q2 2026.
  • Protara Therapeutics made up ﹤0.01% of Dmitry Balyasny's portfolio in Q2 2026, its #1483 holding.
  • Dmitry Balyasny first reported a position in Protara Therapeutics in Q1 2025 and has held it in 2 quarters since.
  • 118 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.